Publications 2024

Bai B, Wise JF, Vodák D, Nakken S, Sharma A, Blaker YN, Brodtkorb M, Hilden V, Trøen G, Ren W, Lorenz S, Lawrence MS, Myklebost O, Kimby E, Pan-Hammarström Q, Steen CB, Meza-Zepeda LA, Beiske K, Smeland EB, Hovig E, Lingjærde OC, Holte H, Myklebust JH (2024)
Multi-omics profiling of longitudinal samples reveals early genomic changes in follicular lymphoma
Blood Cancer J, 14 (1), 147
DOI 10.1038/s41408-024-01124-5, PubMed 39191762

Meriranta L, Sorri S, Huse K, Liu X, Spasevska I, Zafar S, Chowdhury I, Dufva O, Sahlberg E, Tandarić L, Karjalainen-Lindsberg ML, Hyytiäinen M, Varjosalo M, Myklebust JH, Leppä S (2024)
Disruption of KLHL6 Fuels Oncogenic Antigen Receptor Signaling in B-Cell Lymphoma
Blood Cancer Discov, 5 (5), 331-352
DOI 10.1158/2643-3230.BCD-23-0182, PubMed 38630892

Publications 2023

Casey NP, Klee CH, Fåne A, Caulier B, Graczyk-Jarzynka A, Krawczyk M, Fidyt K, Josefsson SE, Köksal H, Dillard P, Patkowska E, Firczuk M, Smeland EB, Winiarska M, Myklebust JH, Inderberg EM, Wälchli S (2023)
Efficient chimeric antigen receptor targeting of a central epitope of CD22
J Biol Chem, 299 (7), 104883
DOI 10.1016/j.jbc.2023.104883, PubMed 37269947

Spasevska I, Sharma A, Steen CB, Josefsson SE, Blaker YN, Kolstad A, Rustad EH, Meyer S, Isaksen K, Chellappa S, Kushekhar K, Beiske K, Førsund MS, Spetalen S, Holte H, Østenstad B, Brodtkorb M, Kimby E, Olweus J, Taskén K, Newman AM, Lorenz S, Smeland EB, Alizadeh AA, Huse K et al. (2023)
Diversity of intratumoral regulatory T cells in B-cell non-Hodgkin lymphoma
Blood Adv, 7 (23), 7216-7230
DOI 10.1182/bloodadvances.2023010158, PubMed 37695745

Publications 2022

Huse K, Bai B, Hilden VI, Bollum LK, Våtsveen TK, Munthe LA, Smeland EB, Irish JM, Wälchli S, Myklebust JH (2022)
Mechanism of CD79A and CD79B Support for IgM+ B Cell Fitness through B Cell Receptor Surface Expression
J Immunol, 209 (10), 2042-2053
DOI 10.4049/jimmunol.2200144, PubMed 36426942

Publications 2021

Oksvold MP, Berglund UW, Gad H, Bai B, Stokke T, Rein ID, Pham T, Sanjiv K, Øy GF, Norum JH, Smeland EB, Myklebust JH, Helleday T, Våtsveen TK (2021)
Karonudib has potent anti-tumor effects in preclinical models of B-cell lymphoma
Sci Rep, 11 (1), 6317
DOI 10.1038/s41598-021-85613-8, PubMed 33737576

Rye IH, Huse K, Josefsson SE, Kildal W, Danielsen HE, Schlichting E, Garred Ø, Riis ML, Osbreac, Lingjaerde OC, Myklebust JH, Russnes HG (2021)
Breast cancer metastasis: immune profiling of lymph nodes reveals exhaustion of effector T cells and immunosuppression
Mol Oncol, 16 (1), 88-103
DOI 10.1002/1878-0261.13047, PubMed 34165864

Spasevska I, Myklebust JH (2021)
What It Takes to Transform a T Cell
Cancer Res, 81 (12), 3160-3161
DOI 10.1158/0008-5472.CAN-21-0784, PubMed 34224376

Steen CB, Luca BA, Esfahani MS, Azizi A, Sworder BJ, Nabet BY, Kurtz DM, Liu CL, Khameneh F, Advani RH, Natkunam Y, Myklebust JH, Diehn M, Gentles AJ, Newman AM, Alizadeh AA (2021)
The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma
Cancer Cell, 39 (10), 1422-1437.e10
DOI 10.1016/j.ccell.2021.08.011, PubMed 34597589

Publications 2020

Bai B, Myklebust JH, Wälchli S (2020)
Gene Editing in B-Lymphoma Cell Lines Using CRISPR/Cas9 Technology
Methods Mol Biol, 2115, 445-454
DOI 10.1007/978-1-0716-0290-4_25, PubMed 32006416

Isaksen KT, Beiske K, Smeland EB, Jørgensen J, Brodtkorb M, Myklebust JH, Jerkeman M, Meriranta L, Karjalainen-Lindsberg ML, Leppä S, Scott DW, Holte H, Blaker YN (2020)
The DLBCL90 gene-expression assay identifies double-hit lymphomas with high sensitivity in patients from two phase II clinical trials with high-risk diffuse large B-cell lymphoma
EJHaem, 2 (1), 104-108
DOI 10.1002/jha2.109, PubMed 35846101

Köksal H, Dillard P, Juzeniene A, Kvalheim G, Smeland EB, Myklebust JH, Inderberg EM, Wälchli S (2020)
Combinatorial CAR design improves target restriction
J Biol Chem, 296, 100116
DOI 10.1074/jbc.RA120.016234, PubMed 33234592

Majzner RG, Rietberg SP, Sotillo E, Dong R, Vachharajani VT, Labanieh L, Myklebust JH, Kadapakkam M, Weber EW, Tousley AM, Richards RM, Heitzeneder S, Nguyen SM, Wiebking V, Theruvath J, Lynn RC, Xu P, Dunn AR, Vale RD, Mackall CL (2020)
Tuning the Antigen Density Requirement for CAR T-cell Activity
Cancer Discov, 10 (5), 702-723
DOI 10.1158/2159-8290.CD-19-0945, PubMed 32193224

Wise JF, Nakken S, Steen CB, Vodák D, Trøen G, Johannessen B, Lingjærde OC, Hilden V, Blaker YN, Bai B, Aasheim LB, Pasanen A, Lorenz S, Sveen A, Lothe RA, Myklebost O, Leppä S, Meza-Zepeda LA, Beiske K, Lawrence MS, Hovig E, Myklebust JH, Smeland EB, Holte H (2020)
Mutational dynamics and immune evasion in diffuse large B-cell lymphoma explored in a relapse-enriched patient series
Blood Adv, 4 (9), 1859-1866
DOI 10.1182/bloodadvances.2019001325, PubMed 32374878

Publications 2019

Huse K, Wogsland CE, Polikowsky HG, Diggins KE, Smeland EB, Myklebust JH, Irish JM (2019)
Human Germinal Center B Cells Differ from Naïve and Memory B Cells in CD40 Expression and CD40L-Induced Signaling Response
Cytometry A, 95 (4), 442-449
DOI 10.1002/cyto.a.23737, PubMed 30838773

Josefsson SE, Beiske K, Blaker YN, Førsund MS, Holte H, Østenstad B, Kimby E, Köksal H, Wälchli S, Bai B, Smeland EB, Levy R, Kolstad A, Huse K, Myklebust JH (2019)
TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma
Cancer Immunol Res, 7 (3), 355-362
DOI 10.1158/2326-6066.CIR-18-0351, PubMed 30659053

Köksal H, Dillard P, Josefsson SE, Maggadottir SM, Pollmann S, Fåne A, Blaker YN, Beiske K, Huse K, Kolstad A, Holte H, Kvalheim G, Smeland EB, Myklebust JH, Inderberg EM, Wälchli S (2019)
Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma
Blood Adv, 3 (8), 1230-1243
DOI 10.1182/bloodadvances.2018029678, PubMed 30979721

Mensali N, Dillard P, Hebeisen M, Lorenz S, Theodossiou T, Myhre MR, Fåne A, Gaudernack G, Kvalheim G, Myklebust JH, Inderberg EM, Wälchli S (2019)
NK cells specifically TCR-dressed to kill cancer cells
EBioMedicine, 40, 106-117
DOI 10.1016/j.ebiom.2019.01.031, PubMed 30665853

Steen CB, Leich E, Myklebust JH, Lockmer S, Wise JF, Wahlin BE, Østenstad B, Liestøl K, Kimby E, Rosenwald A, Smeland EB, Holte H, Lingjærde OC, Brodtkorb M (2019)
A clinico-molecular predictor identifies follicular lymphoma patients at risk of early transformation after first-line immunotherapy
Haematologica, 104 (10), e460-e464
DOI 10.3324/haematol.2018.209080, PubMed 30846496

Publications 2018

Holte H, Beiske K, Boyle M, Trøen G, Blaker YN, Myklebust J, Kvaløy S, Rosenwald A, Lingjaerde OC, Rimsza LM, Smeland EB, Scott DW, Kolstad A (2018)
The MCL35 gene expression proliferation assay predicts high-risk MCL patients in a Norwegian cohort of younger patients given intensive first line therapy
Br J Haematol, 183 (2), 225-234
DOI 10.1111/bjh.15518, PubMed 30080252

Våtsveen TK, Myhre MR, Steen CB, Wälchli S, Lingjærde OC, Bai B, Dillard P, Theodossiou TA, Holien T, Sundan A, Inderberg EM, Smeland EB, Myklebust JH, Oksvold MP (2018)
Artesunate shows potent anti-tumor activity in B-cell lymphoma
J Hematol Oncol, 11 (1), 23
DOI 10.1186/s13045-018-0561-0, PubMed 29458389

Publications 2017

Bollum LK, Huse K, Oksvold MP, Bai B, Hilden VI, Forfang L, Yoon SO, Wälchli S, Smeland EB, Myklebust JH (2017)
BMP-7 induces apoptosis in human germinal center B cells and is influenced by TGF-β receptor type I ALK5
PLoS One, 12 (5), e0177188
DOI 10.1371/journal.pone.0177188, PubMed 28489883

Inderberg EM, Mensali N, Oksvold MP, Fallang LE, Fåne A, Skorstad G, Stenvik GE, Progida C, Bakke O, Kvalheim G, Myklebust JH, Wälchli S (2017)
Human c-SRC kinase (CSK) overexpression makes T cells dummy
Cancer Immunol Immunother, 67 (4), 525-536
DOI 10.1007/s00262-017-2105-9, PubMed 29248956

Josefsson SE, Huse K, Kolstad A, Beiske K, Pende D, Steen CB, Inderberg EM, Lingjærde OC, Østenstad B, Smeland EB, Levy R, Irish JM, Myklebust JH (2017)
T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling
Clin Cancer Res, 24 (4), 870-881
DOI 10.1158/1078-0432.CCR-17-2337, PubMed 29217528

Taraldsrud E, Fevang B, Jørgensen SF, Moltu K, Hilden V, Taskén K, Aukrust P, Myklebust JH, Olweus J (2017)
Defective IL-4 signaling in T cells defines severe common variable immunodeficiency
J Autoimmun, 81, 110-119
DOI 10.1016/j.jaut.2017.04.004, PubMed 28476239

Wogsland CE, Greenplate AR, Kolstad A, Myklebust JH, Irish JM, Huse K (2017)
Mass Cytometry of Follicular Lymphoma Tumors Reveals Intrinsic Heterogeneity in Proteins Including HLA-DR and a Deficit in Nonmalignant Plasmablast and Germinal Center B-Cell Populations
Cytometry B Clin Cytom, 92 (1), 79-87
DOI 10.1002/cyto.b.21498, PubMed 27933753

Publications 2016

Blaker YN, Spetalen S, Brodtkorb M, Lingjaerde OC, Beiske K, Østenstad B, Sander B, Wahlin BE, Melen CM, Myklebust JH, Holte H, Delabie J, Smeland EB (2016)
The tumour microenvironment influences survival and time to transformation in follicular lymphoma in the rituximab era
Br J Haematol, 175 (1), 102-14
DOI 10.1111/bjh.14201, PubMed 27341313

Holm KL, Indrevaer RL, Myklebust JH, Kolstad A, Moskaug JØ, Naderi EH, Blomhoff HK (2016)
Myeloid cell leukaemia 1 has a vital role in retinoic acid-mediated protection of Toll-like receptor 9-stimulated B cells from spontaneous and DNA damage-induced apoptosis
Immunology, 149 (1), 62-73
DOI 10.1111/imm.12629, PubMed 27278254

Myklebust JH, Brody J, Kohrt HE, Kolstad A, Czerwinski DK, Wälchli S, Green MR, Trøen G, Liestøl K, Beiske K, Houot R, Delabie J, Alizadeh AA, Irish JM, Levy R (2016)
Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling
Blood, 129 (6), 759-770
DOI 10.1182/blood-2016-05-718494, PubMed 28011673

Taraldsrud E, Aukrust P, Jørgensen S, Lingjærde OC, Olweus J, Myklebust JH, Fevang B (2016)
Patterns of constitutively phosphorylated kinases in B cells are associated with disease severity in common variable immunodeficiency
Clin Immunol, 175, 69-74
DOI 10.1016/j.clim.2016.11.014, PubMed 27919819

Publications 2015

Blix ES, Kildal AB, Bertelsen E, Waage A, Myklebust JH, Kolstad A, Husebekk A (2015)
Content of endothelial progenitor cells in autologous stem cell grafts predict survival after transplantation for multiple myeloma
Biol Blood Marrow Transplant, 21 (5), 840-7
DOI 10.1016/j.bbmt.2014.12.027, PubMed 25689789

Dale Rein I, Stokke C, Jalal M, Myklebust JH, Patzke S, Stokke T (2015)
New distinct compartments in the G2 phase of the cell cycle defined by the levels of γH2AX
Cell Cycle, 14 (20), 3261-9
DOI 10.1080/15384101.2015.1087617, PubMed 26317799

Oksvold MP, Duyvestyn JM, Dagger SA, Taylor SJ, Forfang L, Myklebust JH, Smeland EB, Langdon WY (2015)
The targeting of human and mouse B lymphocytes by dasatinib
Exp Hematol, 43 (5), 352-363.e4
DOI 10.1016/j.exphem.2015.01.008, PubMed 25641047

Publications 2013

Arita A, McFarland DC, Myklebust JH, Parekh S, Petersen B, Gabrilove J, Brody JD (2013)
Signaling pathways in lymphoma: pathogenesis and therapeutic targets
Future Oncol, 9 (10), 1549-71
DOI 10.2217/fon.13.113, PubMed 24106904

Brodtkorb M, Lingjærde OC, Huse K, Trøen G, Hystad M, Hilden VI, Myklebust JH, Leich E, Rosenwald A, Delabie J, Holte H, Smeland EB (2013)
Whole-genome integrative analysis reveals expression signatures predicting transformation in follicular lymphoma
Blood, 123 (7), 1051-4
DOI 10.1182/blood-2013-07-512392, PubMed 24357726

Green MR, Gentles AJ, Nair RV, Irish JM, Kihira S, Liu CL, Kela I, Hopmans ES, Myklebust JH, Ji H, Plevritis SK, Levy R, Alizadeh AA (2013)
Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma
Blood, 121 (9), 1604-11
DOI 10.1182/blood-2012-09-457283, PubMed 23297126

Myklebust JH, Irish JM, Brody J, Czerwinski DK, Houot R, Kohrt HE, Timmerman J, Said J, Green MR, Delabie J, Kolstad A, Alizadeh AA, Levy R (2013)
High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells
Blood, 121 (8), 1367-76
DOI 10.1182/blood-2012-04-421826, PubMed 23297127

Publications 2012

Bakkebø M, Huse K, Hilden VI, Forfang L, Myklebust JH, Smeland EB, Oksvold MP (2012)
SARA is dispensable for functional TGF-β signaling
FEBS Lett, 586 (19), 3367-72
DOI 10.1016/j.febslet.2012.07.027, PubMed 22819827

Blix ES, Irish JM, Husebekk A, Delabie J, Forfang L, Tierens AM, Myklebust JH, Kolstad A (2012)
Phospho-specific flow cytometry identifies aberrant signaling in indolent B-cell lymphoma
BMC Cancer, 12, 478
DOI 10.1186/1471-2407-12-478, PubMed 23072591

Blix ES, Irish JM, Husebekk A, Delabie J, Tierens AM, Myklebust JH, Kolstad A (2012)
Altered BCR and CD40 signalling are associated with clinical outcome in small lymphocytic lymphoma/chronic lymphocytic leukaemia and marginal zone lymphoma patients
Br J Haematol, 159 (5), 604-8
DOI 10.1111/bjh.12073, PubMed 23043253

Huse K, Bakkebø M, Wälchli S, Oksvold MP, Hilden VI, Forfang L, Bredahl ML, Liestøl K, Alizadeh AA, Smeland EB, Myklebust JH (2012)
Role of Smad proteins in resistance to BMP-induced growth inhibition in B-cell lymphoma
PLoS One, 7 (10), e46117
DOI 10.1371/journal.pone.0046117, PubMed 23049692

Publications 2011

Alizadeh AA, Gentles AJ, Alencar AJ, Liu CL, Kohrt HE, Houot R, Goldstein MJ, Zhao S, Natkunam Y, Advani RH, Gascoyne RD, Briones J, Tibshirani RJ, Myklebust JH, Plevritis SK, Lossos IS, Levy R (2011)
Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment
Blood, 118 (5), 1350-8
DOI 10.1182/blood-2011-03-345272, PubMed 21670469

Huse K, Bakkebø M, Oksvold MP, Forfang L, Hilden VI, Stokke T, Smeland EB, Myklebust JH (2011)
Bone morphogenetic proteins inhibit CD40L/IL-21-induced Ig production in human B cells: differential effects of BMP-6 and BMP-7
Eur J Immunol, 41 (11), 3135-45
DOI 10.1002/eji.201141558, PubMed 21898381

Tkacz-Stachowska K, Lund-Andersen C, Velissarou A, Myklebust JH, Stokke T, Syljuåsen RG (2011)
The amount of DNA damage needed to activate the radiation-induced G2 checkpoint varies between single cells
Radiother Oncol, 101 (1), 24-7
DOI 10.1016/j.radonc.2011.05.060, PubMed 21722983

Publications 2010

Chao MP, Alizadeh AA, Tang C, Myklebust JH, Varghese B, Gill S, Jan M, Cha AC, Chan CK, Tan BT, Park CY, Zhao F, Kohrt HE, Malumbres R, Briones J, Gascoyne RD, Lossos IS, Levy R, Weissman IL, Majeti R (2010)
Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma
Cell, 142 (5), 699-713
DOI 10.1016/j.cell.2010.07.044, PubMed 20813259

Irish JM, Myklebust JH, Alizadeh AA, Houot R, Sharman JP, Czerwinski DK, Nolan GP, Levy R (2010)
B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progression
Proc Natl Acad Sci U S A, 107 (29), 12747-54
DOI 10.1073/pnas.1002057107, PubMed 20543139

Publications 2009

Gentles AJ, Alizadeh AA, Lee SI, Myklebust JH, Shachaf CM, Shahbaba B, Levy R, Koller D, Plevritis SK (2009)
A pluripotency signature predicts histologic transformation and influences survival in follicular lymphoma patients
Blood, 114 (15), 3158-66
DOI 10.1182/blood-2009-02-202465, PubMed 19636063

Houot R, Goldstein MJ, Kohrt HE, Myklebust JH, Alizadeh AA, Lin JT, Irish JM, Torchia JA, Kolstad A, Chen L, Levy R (2009)
Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion
Blood, 114 (16), 3431-8
DOI 10.1182/blood-2009-05-223958, PubMed 19641184

Luo RF, Zhao S, Tibshirani R, Myklebust JH, Sanyal M, Fernandez R, Gratzinger D, Marinelli RJ, Lu ZS, Wong A, Levy R, Levy S, Natkunam Y (2009)
CD81 protein is expressed at high levels in normal germinal center B cells and in subtypes of human lymphomas
Hum Pathol, 41 (2), 271-80
DOI 10.1016/j.humpath.2009.07.022, PubMed 20004001

Publications 2007

Cabezón T, Celis JE, Skibshøj I, Klingelhöfer J, Grigorian M, Gromov P, Rank F, Myklebust JH, Maelandsmo GM, Lukanidin E, Ambartsumian N (2007)
Expression of S100A4 by a variety of cell types present in the tumor microenvironment of human breast cancer
Int J Cancer, 121 (7), 1433-44
DOI 10.1002/ijc.22850, PubMed 17565747

Hystad ME, Myklebust JH, Bø TH, Sivertsen EA, Rian E, Forfang L, Munthe E, Rosenwald A, Chiorazzi M, Jonassen I, Staudt LM, Smeland EB (2007)
Characterization of early stages of human B cell development by gene expression profiling
J Immunol, 179 (6), 3662-71
DOI 10.4049/jimmunol.179.6.3662, PubMed 17785802

Sivertsen EA, Huse K, Hystad ME, Kersten C, Smeland EB, Myklebust JH (2007)
Inhibitory effects and target genes of bone morphogenetic protein 6 in Jurkat TAg cells
Eur J Immunol, 37 (10), 2937-48
DOI 10.1002/eji.200636759, PubMed 17899540

Publications 2006

Kersten C, Dosen G, Myklebust JH, Sivertsen EA, Hystad ME, Smeland EB, Rian E (2006)
BMP-6 inhibits human bone marrow B lymphopoiesis--upregulation of Id1 and Id3
Exp Hematol, 34 (1), 72-81
DOI 10.1016/j.exphem.2005.09.010, PubMed 16413393

Sivertsen EA, Hystad ME, Gutzkow KB, Døsen G, Smeland EB, Blomhoff HK, Myklebust JH (2006)
PI3K/Akt-dependent Epo-induced signalling and target genes in human early erythroid progenitor cells
Br J Haematol, 135 (1), 117-28
DOI 10.1111/j.1365-2141.2006.06252.x, PubMed 16965383

Publications 2005

Kersten C, Sivertsen EA, Hystad ME, Forfang L, Smeland EB, Myklebust JH (2005)
BMP-6 inhibits growth of mature human B cells; induction of Smad phosphorylation and upregulation of Id1
BMC Immunol, 6, 9
DOI 10.1186/1471-2172-6-9, PubMed 15877825

Torlakovic E, Malecka A, Myklebust JH, Tierens A, Aasheim HC, Nesland JM, Smeland E, Kvaløy S, Delabie J (2005)
PU.1 protein expression has a positive linear association with protein expression of germinal centre B cell genes including BCL-6, CD10, CD20 and CD22: identification of PU.1 putative binding sites in the BCL-6 promotor
J Pathol, 206 (3), 312-9
DOI 10.1002/path.1777, PubMed 15892171

Publications 2002

Myklebust JH, Blomhoff HK, Rusten LS, Stokke T, Smeland EB (2002)
Activation of phosphatidylinositol 3-kinase is important for erythropoietin-induced erythropoiesis from CD34(+) hematopoietic progenitor cells
Exp Hematol, 30 (9), 990-1000
DOI 10.1016/s0301-472x(02)00868-8, PubMed 12225790

Publications 2001

Myklebust JH (2001)
Regulation of apoptosis and differentiation in human bonemarrow hematopoietic progenitor cells
In Series of dissertations submitted to the Faculty of Medicine, University of Oslo, Unipub, Oslo, no. 2, 1 b. (flere pag.)
BIBSYS 020188994, ISBN 82-7633-174-2

Publications 2000

Josefsen D, Myklebust JH, Lømo J, Sioud M, Blomhoff HK, Smeland EB (2000)
Differential expression of bcl-2 homologs in human CD34(+) hematopoietic progenitor cells induced to differentiate into erythroid or granulocytic cells
Stem Cells, 18 (4), 261-72
DOI 10.1634/stemcells.18-4-261, PubMed 10924092

Myklebust JH, Smeland EB, Josefsen D, Sioud M (2000)
Protein kinase C-alpha isoform is involved in erythropoietin-induced erythroid differentiation of CD34(+) progenitor cells from human bone marrow
Blood, 95 (2), 510-8
DOI 10.1182/blood.V95.2.510, PubMed 10627456

Publications 1999

Fosså A, Brandhorst D, Myklebust JH, Seeber S, Nowrousian MR (1999)
Relation between S-phase fraction of myeloma cells and anemia in patients with multiple myeloma
Exp Hematol, 27 (11), 1621-6
DOI 10.1016/s0301-472x(99)00105-8, PubMed 10560909

Josefsen D, Myklebust JH, Lynch DH, Stokke T, Blomhoff HK, Smeland EB (1999)
Fas ligand promotes cell survival of immature human bone marrow CD34+CD38- hematopoietic progenitor cells by suppressing apoptosis
Exp Hematol, 27 (9), 1451-9
DOI 10.1016/s0301-472x(99)00073-9, PubMed 10480436

Myklebust JH, Josefsen D, Blomhoff HK, Levy FO, Naderi S, Reed JC, Smeland EB (1999)
Activation of the cAMP signaling pathway increases apoptosis in human B-precursor cells and is associated with downregulation of Mcl-1 expression
J Cell Physiol, 180 (1), 71-80
DOI 10.1002/(SICI)1097-4652(199907)180:1<71::AID-JCP8>3.0.CO;2-N, PubMed 10362019

Publications 1998

Saeterdal I, thor Straten P, Myklebust JH, Kirkin AF, Gjertsen MK, Gaudernack G (1998)
Generation and characterization of gp100 peptide-specific NK-T cell clones
Int J Cancer, 75 (5), 794-803
DOI 10.1002/(sici)1097-0215(19980302)75:5<794::aid-ijc21>3.0.co;2-5, PubMed 9495251